Viracta Therapeutics Announces Topline Nana-val Results From Stage 1 of the NAVAL-1 Trial In Patients With Relapsed Or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics announced positive topline results from Stage 1 of the NAVAL-1 trial for Nana-val, a combination treatment for Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma. The treatment showed a 50% overall response rate and a 20% complete response rate in the intent-to-treat population, with even higher efficacy in the efficacy-evaluable population. The results, which demonstrate greater efficacy than nanatinostat monotherapy, were presented at a joint annual congress in Taiwan.
April 15, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viracta Therapeutics' positive trial results for Nana-val indicate a significant advancement in treating Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma, potentially boosting investor confidence and stock value.
The announcement of positive trial results typically leads to increased investor confidence, which can drive up the stock price. Given the significant efficacy demonstrated by Nana-val, especially compared to monotherapy, this news is likely to be viewed positively by the market. The detailed results and the presentation at a prestigious congress further validate the potential of Nana-val, making this news highly relevant and important for investors in VIRX.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100